Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines
Latest Information Update: 06 Aug 2018
At a glance
- Drugs Tezosentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Proof of concept; Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 15 Aug 2014 New trial record
- 27 Jun 2012
- 31 May 2011